Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 249

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance

Ziol, Marianne, Poté, Nicolas, Amaddeo, Giuliana, Laurent, Alexis, Nault, Jean‐Charles, Oberti, Frédéric, Costentin, Charlotte, Michalak, Sophie, Bouattour, Mohamed, Francoz, Claire, Pageaux, Georges Philippe, Ramos, Jeanne, Decaens, Thomas, Luciani, Alain, Guiu, Boris, Vilgrain, Valérie, Aubé, Christophe, Derman, Jonathan, Charpy, Cécile, Zucman‐Rossi, Jessica, Barget, Nathalie, Seror, Olivier, Ganne‐Carrié, Nathalie, Paradis, Valérie, Calderaro, Julien·2018·Hepatology

Abstract

We recently identified a histological subtype of hepatocellular carcinoma (HCC), designated as "macrotrabecular-massive" (MTM-HCC) and associated with specific molecular features. In order to assess the clinical relevance of this variant, we investigated its prognostic value in two large series of patients with HCC treated by either surgical resection or radiofrequency ablation (RFA). We retrospectively included 237 HCC surgical samples and 284 HCC liver biopsies from patients treated by surgical resection and RFA, respectively. Histological slides were reviewed by pathologists specialized in liver disease, and the MTM-HCC subtype was defined by the presence of a predominant (>50%) macrotrabecular architecture (more than six cells thick). The main clinical and biological features were recorded at baseline. Clinical endpoints were early and overall recurrence. The MTM-HCC subtype was identified in 12% of the whole cohort (16% of surgically resected samples, 8.5% of liver biopsy samples). It was associated at baseline with known poor prognostic factors (tumor size, alpha-fetoprotein level, satellite nodules, and vascular invasion). Multivariate analysis showed that MTM-HCC subtype was an independent predictor of early and overall recurrence (surgical series: hazard ratio, 3.03; 95% confidence interval, 1.38-6.65; P = 0.006; and 2.76; 1.63-4.67; P < 0.001; RFA series: 2.37; 1.36-4.13; P = 0.002; and 2.19; 1.35-3.54; P = 0.001, respectively). Its prognostic value was retained even after patient stratification according to common clinical, biological, and pathological features of aggressiveness. No other baseline parameter was independently associated with recurrence in the RFA series. CONCLUSION: The MTM-HCC subtype, reliably observed in 12% of patients eligible for curative treatment, represents an aggressive form of HCC that may require more specific therapeutic strategies. (Hepatology 2018;68:103-112).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.29762

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 249

Metadata

Authors
Ziol, M., Poté, N., Amaddeo, G., Laurent, A., Nault, J., Oberti, F., Costentin, C., Michalak, S., Bouattour, M., Francoz, C., Pageaux, G. P., Ramos, J., Decaens, T., Luciani, A., Guiu, B., Vilgrain, V., Aubé, C., Derman, J., Charpy, C., Zucman‐Rossi, J., Barget, N., Seror, O., Ganne‐Carrié, N., Paradis, V., & Calderaro, J.
Venue
Hepatology
Published
2018-07
Volume
68
Issue
1
Pages
103-112
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2780918397
Cited by
249
References
6
FWCI
7.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. https://app.cochat.ai/papers/10.1002/hep.29762
The paper
Ziol, M., Poté, N., Amaddeo, G., Laurent, A., Nault, J., Oberti, F., Costentin, C., Michalak, S., Bouattour, M., Francoz, C., Pageaux, G. P., Ramos, J., Decaens, T., Luciani, A., Guiu, B., Vilgrain, V., Aubé, C., Derman, J., Charpy, C., . . . Calderaro, J. (2018). Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology. https://doi.org/10.1002/hep.29762

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.